与IV期非小细胞肺癌免疫疗法的有效性相关的个人和临床特征
Krishna H Patel1, Naomi Alpert1, Stephanie Tuminello2
1Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Translational lung cancer research
|July 10, 2023
概括
化疗免疫疗法改善了转移性非小细胞肺癌 (NSCLC) 的存活率. 男性可能从这种治疗中获益更多,这表明个性化方法可以在NSCLC患者中获得更好的结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺癌研究研究 肺癌研究
背景情况:
- 转移性非小细胞肺癌 (NSCLC) 免疫治疗反应率低,存活率可变.
- 个人和临床特征可能会影响化疗免疫疗法的有效性.
- 现有研究受到概括性和无法调整混因素的限制.
研究的目的:
- 探索个人和临床特征如何调节转移性NSCLC中的化疗免疫疗法的有效性.
- 分析患者层面的数据,以便更好地理解治疗反应.
- 确定可能从化疗免疫疗法中或多或少受益的患者子组.
主要方法:
- 使用监测流行病学和最终结果-医疗保险相关数据的队列研究 (2015年诊断).
- 对IV期NSCLC患者的分析,将化疗免疫疗法与单独化疗进行比较.
- 多变量Cox比例危险回归和倾向性得分匹配,以评估整体存活率 (OS).
主要成果:
- 与单独化疗相比,化疗免疫疗法显著改善了OS (调整HR:0.72).
- 经过化疗免疫疗法,男性的生存状况明显好于女性 (调整HR:0.62) (调整HR:0.81).
- 在倾向性得分匹配后,性别对差异化疗免疫治疗效果具有边界意义 (P=0.0414).
结论:
- 男性可能从转移性NSCLC的化疗免疫治疗中获得更大的益处.
- 有限的证据表明年龄,组织学,种族或并发症显著调节有效性.
- 需要进一步的研究来确定最佳响应者,并根据患者亚群量身定制治疗.
相关概念视频
Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Cancer Vaccines
419
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
419
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cytotoxic T Cells-mediated Immune Response
985
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
985


